Skip to Content

Join the 'Uptravi' group to help and get support from people like you.

Uptravi News

Uptravi Approved for Chronic Lung Disease

Posted 23 Dec 2015 by Drugs.com

TUESDAY, Dec. 22, 2015 – Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant. PAH is high blood pressure that affects arteries that connect the lungs and heart. It causes the heart to work harder, resulting in shortness of breath and ...

FDA Approves Uptravi (selexipag) for Pulmonary Arterial Hypertension

Posted 23 Dec 2015 by Drugs.com

December 22, 2015 – On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation. “Uptravi offers an additional treatment option for patients with pulmonary arterial hypertension,” said Ellis Ung ...

Ask a Question

Further Information

Related Condition Support Groups

Pulmonary Hypertension

Uptravi Patient Information at Drugs.com